KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stryker (SYK) Common Equity (2016 - 2025)

Stryker (SYK) has disclosed Common Equity for 17 consecutive years, with $22.4 billion as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity rose 8.66% to $22.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $22.4 billion, a 8.66% increase, with the full-year FY2025 number at $22.4 billion, up 8.66% from a year prior.
  • Common Equity was $22.4 billion for Q4 2025 at Stryker, up from $21.8 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $22.4 billion in Q4 2025 to a low of -$286.0 million in Q2 2022.
  • A 5-year average of $9.3 billion and a median of $7.5 billion in 2021 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: plummeted 102.22% in 2022, then skyrocketed 54200.0% in 2024.
  • Stryker's Common Equity stood at $1.9 billion in 2021, then rose by 7.62% to $2.0 billion in 2022, then tumbled by 98.13% to $38.0 million in 2023, then surged by 54200.0% to $20.6 billion in 2024, then grew by 8.66% to $22.4 billion in 2025.
  • Per Business Quant, the three most recent readings for SYK's Common Equity are $22.4 billion (Q4 2025), $21.8 billion (Q3 2025), and $4.0 million (Q1 2025).